Search results
Author(s):
Ruth Masterson Creber
Added:
1 year ago
ACC 25 - Findings of the MIGHTy-Heart study shows no difference between mobile integrated healthcare and a traditional transitions of care coordinator approach in 30-day all-cause readmissions or health status.Dr Ruth Masterson Creber (Columbia University, New York, US) joins us onsite at ACC to discuss the findings from MIGHTy-Heart, a comparative effectiveness study that evaluated two different…
View more
Author(s):
Archana Ganapathy
,
Jason N Dungu
,
Anthony D Dimarco
,
et al
Added:
3 months ago
Added:
2 years ago
Source:
Heart Failure 2024
Heart Failure Congress 2024 has unveiled 8 Late-breaking trial sessions for 2024.Heart Failure 2024 will take place at the Lisbon Congress Center in May. Access the full Programme here.For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators, and keep up to date with our Late-Breaker Discussions with Dr Van Spall.Late…
View more
Device Therapies in Heart Failure
Author(s):
Yoel Benarroch
,
Natalie Tapaskar
,
Amin Yehya
Added:
8 months ago
Review Article
Added:
3 months ago
In this episode of Parallax, Dr Ankur Kalra welcomes Dr Rakesh Shah, a former interventional cardiologist, Oxford MBA graduate, and founder of DRS.LINQ. Dr Shah brings a unique perspective on addressing critical delays in heart attack diagnosis through the intersection of clinical medicine, engineering, and business strategy.The conversation explores a pressing challenge in cardiovascular care:…
View more
Joseph G Akar
Research Area(s) / Expertise:
Author
Author(s):
Josip A Borovac
,
Dino Miric
Added:
5 months ago
Author(s):
Karol Mirkowski
,
Ercole Vellone
,
Bernadetta Żółkowska
,
et al
Added:
1 year ago
Author(s):
Ahmad Masri
Added:
7 months ago
HFSA 25 - Aficamten found to significantly improve NYHA and KCCQ-CSS scores in new 96-week data from FOREST-HCM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss findings from the FOREST-HCM trial, examining the sustained safety and efficacy of aficamten in patients with symptomatic nonobstructive hypertrophic cardiomyopathy.This phase 2 open-label study followed 34…
View more
Suneet Mittal
Research Area(s) / Expertise:
Job title: Director of the Electrophysiology Laboratory
Author